← board
FHTX
Foghorn Therapeutics Inc.distress 4/10 · elevated risk$5.16-1%today-23% from 52w high
Oncology 1
Lead: ER+ breast cancer · est. market ~$35B (approx, global)
Revenue
pre-revenue
Liquidity
$88M
Runway
1.0 yrs
Shares 1y
+4%
Price & events
-16.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.0%
1D
+1.8%
1W
+24.6%
1M
-0.6%
3M
-12.2%
6M
-20.2%
1Y
-21.9%
2Y
-46.6%
5Y
-72.9%
All
Overview
- Market Cap
- $302.96M
- Volume
- 2.99K
- 52 Week Range
- $3.53 – $6.68
- Total Shares
- 58.71M
- Float Shares
- 27.41M
- Short %
- 4.98%
- % Held by Insiders
- 14.30%
- % Held by Institutions
- 76.58%
- RVOL
- 0.01x
- Beta
- 2.86
Pipeline stages · 1 programs
FHD-286, Low Dose Cytarabine, Decitabine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-09 | Phase 1 | FHD-286, Low Dose Cytarabine, Decitabine | Advanced Hematologic Malignancy, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Relapsed Myelodysplastic Syndromes, Refractory Myelodysplastic Syndromes, Relapsed Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia | 144 | active not recruiting |
Catalyst news & presentations · 11
- 2027Guided 40%regulatory submissionFiled (NDA/BLA)Selective CBP degrader (FHT-171) · IND anticipated for CBP degraderSEC 8-K
- 2026Guided 40%trial initiationsecondaryCBP degrader program · Initiation of IND-enabling studies for selective CBP degrader CBPd-171SEC 8-K
- 2026Guided 40%trial initiationsecondaryEP300 degrader program · Initiation of IND-enabling studies for selective EP300 degraderSEC 8-K
- 2026Guided 40%trial initiationsecondarySelective EP300 degrader · IND-enabling studiesSEC 8-K
- 2026Guided 40%regulatory submissionFiled (NDA/BLA)Selective CBP degrader · IND-readySEC 8-K
- 2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
- April 2026conferencedata presentationsecondaryFHD-909; CBP degrader; EP300 degrader; ARID1B degrader · Preclinical data for SMARCA2 selective inhibitor FHD-909 and selective CBP, EP300, ARID1B degrader programs presented at the 2026 AACR Annual Meeting.SEC 8-K
- H2 2025conferencedata presentationsecondarySelective EP300 degrader · Program update expected in H2 2025SEC 8-K
- fourth quarter of 2024readoutPhase 1FHD-286 · Topline Phase 1 dose escalation data for FHD-286 in combination with decitabineSEC 8-K
- second half of 2024trial initiationsecondaryPhase 1FHD-909 · Dosing of first patient in Phase 1 trial for FHD-909, a SMARCA2 selective inhibitorSEC 8-K
- by year-end 2024trial initiationsecondarySelective CBP degrader · IND-enabling studies on track to beginSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $11 (+122% upside) · 9 analysts
- 2026-03-12WedbushOutperform
- 2026-03-10HC Wainwright & Co.Buy
- 2026-02-17JefferiesBuy
- 2025-12-18BTIGBuy
- 2025-12-04StifelBuy
- 2025-11-07GuggenheimBuy
Competitors — ER+ breast cancer
Recent news
- 2026-07-15(FHTX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
- 2026-07-13Foghorn Therapeutics(FHTX) Stock Options Chain | Quotes & News - Moomoo
- 2026-07-08H.C. Wainwright Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Maintains Target Price $13 - 富途牛牛
- 2026-07-05FHTX Q1 2026 Earnings: EPS Beat Drives Modest Stock Uptick Amid Pipeline Progress - Operating Margin Analysis - dars.gov.et
- 2026-07-05FHTX - Foghorn Therapeutics Inc Options - Finviz
- 2026-07-03FHTX SEC Filings - Foghorn Therapeutics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
- 2026-07-03Foghorn Therapeutics (FHTX) Surges 5.8%: Is This an Indication of Further Gains? - Yahoo Finance
- 2026-07-02We're Keeping An Eye On Foghorn Therapeutics' (NASDAQ:FHTX) Cash Burn Rate - Moomoo
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.